BioSpace News Archive

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has completed the $5,000,002 private placement of 1,666,668 shares of common stock at a price of $3.00 per share (the “Shares”) on August 4, 2021.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology is a simple but powerful tool for genome editing.

The histopathology services market is projected to reach US$ 35,187.90 million by 2028 from US$ 23,890.44 million in 2021; it is expected to grow at a CAGR of 5.7% from 2021 to 2028.

RNA extraction is an amalgamation of chemical and physical processes involved in the isolation of RNA.

he Debentures incur interest of 8.0% per annum.

Marvel’s compound is a novel patented fluorinated derivative of the US-FDA approved Parkinson’s disease drug Istradefylline (Nourianz®).

Owing to the Covid-19 pandemic, the need for telemedicine and mHealth technologies increased in the healthcare industry for obtaining accurate patient information, linked patient records, interoperability, and cyber security.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter of 2021.

BridgeBio Pharma, Inc. today reported its financial results for the second quarter ended June 30, 2021 and provided an update on the Company’s operations.

Cytocom Inc. today provided shareholders with an update regarding its recent merger with Cleveland BioLabs.